A randomized controlled pilot study demonstrated the feasibility and safety of performing a large clinical trial that is powered to establish whether phosphate lowering reduces fatal and nonfatal cardiovascular events.
Phase 2 randomized placebo-controlled trial demonstrated the safety and efficacy of sevelamer in lowering serum phosphorus levels in children and adolescents.
Of 7 phosphate binders, iron-based agents were optimal when efficacy and safety are considered.
The proportion of patients with serum phosphorus levels within target range rose from 22% to 65% within 6 months of starting ferric citrate treatment.
Use of sevelamer was associated with a 14% decreased risk of death compared with non-use.
Patients receiving educational or behavioral interventions aimed at controlling hyperphosphatemia had an average reduction in phosphate of 0.23 mmol/L more than standard care patients.
Company asks FDA to approve ferric citrate for iron deficiency anemia in patients with non-dialysis dependent chronic kidney disease.
Calcium-based binders, however, are associated with greater odds of all-cause mortality versus sevelamer.
In a study, 61% of hemodialysis patients reported accidentally forgetting to take their medication or otherwise skipping doses unintentionally.
The phosphate binder is a useful treatment for hyperphosphatemia with a relatively low pill burden, researchers say.
Phosphorus targets in patients with chronic kidney disease stage 3 to 4 should be below 4.3 mg/dL, researchers report.
Hyperphosphatemia is present in many who say following diets and binder schedules is easy.
Autonomy support could be an appropriate target for culturally informed strategies to optimize mineral bone health.
A mortality rate increase of 43 cases per 1000 patients was found for calcium-based phosphate binders.
Researchers observe an 81% increase in dialysis patients achieving recommended phosphorus levels after switching to sucroferric oxyhydroxide.
Study of peritoneal dialysis patients showed that they do not adjust binders to match the phosphate content of meals and snacks.
Expert suggests factors beyond poor adherence to a low phosphorus diet and binder therapy may contribute to hyperphosphatemia.
Study compared sucroferric oxyhydroxide and sevelamer carbonate.
Recipients of in-hospital nighttime dialysis experienced a 14.2 gram reduction in left ventricle thickening.
Large European study identifies ranges of phosphorus, calcium, and parathyroid hormone levels with the lowest death risk.
In a study, 45% of hemodialysis patients internationally reported skipping phosphate binder pills at least once in the prior month.
Patients with hyperphosphatemia lowered their phosphorus levels with a dietitian's guidance or cash incentive.
Fracture rates are 2.4- to 3-fold higher than rates found in the general population of children and adolescents.
It had a phosphorus-lowering effect similar to that of sevelamer, but had a lower pill burden.
One-third of patients who missed clinical targets for phosphorus, calcium and/or parathormone remained untreated.
PARIS—Raising the dose of the calcium-free phosphate binder lanthanum carbonate from a lower conventionally used dose of 2,250 or less to 3,000 mg/day may reduce phosphorus levels in patients with chronic kidney disease (CKD) and hyperphosphatemia.
NATIONAL HARBOR, Md.—Dialysis patient underreporting of noncompliance with phosphate binder therapy may contribute to poor phosphorus control, investigators reported at the National Kidney Foundation 2012 Spring Clinical Meetings.
NATIONAL HARBOR, Md.—An investigational iron-based phosphate binder is effective and well tolerated in hemodialysis (HD) patients with hyperphosphatemia, according to data presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
An investigational calcium-free phosphate binder called colestilan is safe and effective for controlling phosphorus in dialysis patients, and it has no impact on calcium levels, researchers reported.
Use of sevelamer rather than calcium-based calcium binders (CBBs) to treat hyperphosphatemia in dialysis patients is associated with a reduction in missed in-center dialysis treatments regardless of dialysis organization size, according to findings published in abstract form as part of Renal Week 2010 in Denver.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)